Last reviewed · How we verify
NCT06584734: EXE-HDF
Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemodialysis Patients
NA trial testing Not exercise in Renal Dialysis in 41 participants. Participants enrolled and being followed up; not accepting new ones.
30 September 2024
Quick facts
| Lead sponsor | Instituto Nacional de Cardiologia Ignacio Chavez |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 41 |
| Start date | 17 September 2023 |
| Primary completion | 30 September 2024 |
| Estimated completion | 30 October 2024 |
| Sites | 1 location across Mexico |
Drugs / interventions tested
- Not exercise
- Exercise during hemodiafiltration session
Conditions studied
- Renal Dialysis — all drugs for Renal Dialysis →
- Hemodiafiltration — all drugs for Hemodiafiltration →
- Diastolic Dysfunction — all drugs for Diastolic Dysfunction →
- Kidney Failure — all drugs for Kidney Failure →
Sponsor
Instituto Nacional de Cardiologia Ignacio Chavez — full company profile →
Who can join
18 and older, any sex, with Renal Dialysis or Hemodiafiltration. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Introduction: Cardiovascular diseases are the leading cause of morbidity and mortality in hemodialysis patients, primarily due to structural cardiac changes that lead to diastolic dysfunction. Furthermore, this population has a high prevalence of sedentary behavior and increased mortality associated with it. Recent studies have implemented exercise regimens in the chronic kidney disease population, demonstrating improvements in various parameters related to cardiovascular disease. Objectives: To evaluate the effect of implementing systematic intradialytic exercise on left ventricular diastolic function. Materials and Methods: This is a quasi-experimental study (before-and-after type) that will be conducted in two phases. In the first phase (rest), both incident and prevalent hemodialysis patients will receive treatment for 3 months. A baseline echocardiogram will be performed and then repeated at the end of the first phase to determine left ventricular diastolic function parameters. The second phase of the study (intradialytic exercise) will take place during the following 3 months, with an echocardiogram performed at the beginning and end of this phase. Systematic, prescribed, and supervised intradialytic aerobic exercise (intradialytic pedaling) will be implemented. Additionally, a 6-minute walk test and a validated physical activity questionnaire will be administered monthly during both phases of the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06584734
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Renal Dialysis
Currently open trials in the same condition.
- NCT06742827 — Educational Intervention and Adherence · NA · active not recruiting
- NCT06568835 — The Effect of Active Exercise on Maintenance Haemodialysis Patients · NA · recruiting
- NCT05755503 — Toxicokinetics of Protein-bound Uremic Toxins in ESRD Patients · recruiting
Other Instituto Nacional de Cardiologia Ignacio Chavez trials
Trials by the same sponsor.
- NCT06881940 — Cardiac Rehabilitation Program on the Prevention of Cardiotoxicity in Breast Cancer Patients Undergoing Treatment With A · NA · not yet recruiting
- NCT06342141 — Empagliflozin for No-reflow Phenomenon in PCI for STEMI · Phase 2 · active not recruiting
- NCT06521307 — Impact of Nicotinamide Riboside (NR) on Kidney Function in Patients Undergoing Cardiac Surgery · NA · not yet recruiting
- NCT06013813 — Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI · NA · unknown
- NCT05580510 — " Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in · Phase 2, PHASE3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06584734 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Instituto Nacional de Cardiologia Ignacio Chavez
- Last refreshed: 5 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06584734.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing